IN THIS ISSUE

Highlighted research articles .................................. 983

NEWS IN BRIEF

Important news stories affecting the community ............ 988

NEWS IN DEPTH

IDH Inhibitors Target Common Glioma Mutation .......... 992

RESEARCH WATCH

Selected highlights of recent articles of exceptional significance from the cancer literature .......... 993

ONLINE

For more News and Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.

RESEARCH BRIEF

Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers .......... 1022

Précis: Neoantigens in cancers with low numbers of mutations are similarly recognized by tumor-infiltrating lymphocytes, with implications for improving immunotherapy.

RESEARCH ARTICLES

First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study .......... 1036

Précis: A phase I dose-escalation study evaluates the safety and pharmacokinetics of the RNA Polymerase I inhibitor CX-5461 in patients with advanced hematologic cancers.

Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia .......... 1050

Précis: Targeted next-generation sequencing of matched pretreatment and progressive samples from patients with AML on gilteritinib identified multiple secondary gilteritinib resistance mechanisms.

See commentary, p. 998

REVIEWS

The Metabolic Basis of Kidney Cancer ....................... 1006
W.M. Linehan, L.S. Schmidt, D.R. Crooks, D. Wei, R. Srinivasan, M. Lang, and C.J. Ricketts

Précis: The metabolic basis of kidney cancer is discussed, including the role of metabolic pathways in the development and progression of kidney cancer.
TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma ..........................1064


Précis: The irreversible FGFR inhibitor TAS-120 has clinical activity against FGFR2 mutations that confer resistance to FGFR inhibitors in patients with FGFR2-altered intrahepatic cholangiocarcinoma.

Aging Human Hematopoietic Stem Cells Manifest Profound Epigenetic Reprogramming of Enhancers That May Predispose to Leukemia ............1080


Précis: Human hematopoietic stem cells undergo age-associated genome-wide epigenomic changes that target developmental and cancer-related pathways and may increase susceptibility to myeloid malignancies.

Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts ..............1102


Précis: A previously unknown class of cancer-associated fibroblasts with unique immune properties may contribute to the immunosuppressive PDAC microenvironment.

See commentary, p. 1001

β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma ....1124


Précis: A mouse model of hepatocellular carcinoma reveals that β-catenin activation leads to anti–PD-1 resistance via faulty immune surveillance.

See commentary, p. 1003

Editor’s Note

Editor’s Note: Increased Levels of COX-2 and Prostaglandin E2 Contribute to Elevated Aromatase Expression in Inflamed Breast Tissue of Obese Women ........ 1142

For more information please visit http://www.aacrjournals.org